Coming to fruition
Drugs to Watch 2025 - a new generation of breakthrough treatments making their way to market and bringing hope to patients
We are now witnessing the coming to fruition of a host of technologies that have been in development for many years, in some cases decades – GLP-1 drugs for weight loss, antibody drug conjugates and bispecific antibodies for cancer and more, radiopharmaceuticals, cell and gene therapies, etc. – as the long slog of painstakingly iterative R&D work culminates in major advances.
As a result, a new generation of breakthrough treatments is now making its way to market, bringing hope to patients – if often at great cost, since these miracle drugs were tremendously expensive to produce.
Introducing Drugs to Watch 2025
Eleven new and emerging therapeutics with the potential to transform treatment paradigms and/or become blockbusters within the next five years, according to Clarivate data and predictive analytics.
Methodology
To identify this year’s Drugs to Watch 2025 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and 11 integrated data sets that span the R&D and commercialization lifecycle.
Key trends to watch
Regulators are increasingly demanding more of biopharma companies as they seek to ensure that the patient voice is heard while pushing aggressively to address treatment gaps with approvals of novel products and platforms. The rise of radiopharmaceuticals and the triumph of new approaches to weight loss demonstrate what industry and agencies can accomplish for public health.
Download the report to learn more about key trends emerging in 2025.
Related insights
Real world data reveal how diseases manifest in diverse populations
The prevalence and co-occurrence of immune-mediated inflammatory diseases (IMIDs) like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity among U.S. adults. That’s the upshot of a retrospective…
